The Efficacy of Adjunctive N-Acetylcysteine in Major Depressive Disorder: A Double-Blind, Randomized, Placebo-Controlled Trial
Michael Berk, Olivia M Dean, Sue M Cotton, Susan Jeavons, Michelle Tanious, Kristy Kohlmann, Karen Hewitt, Kirsteen Moss, Christine Allwang, Ian Schapkaitz, Jenny Robbins, Heidi Cobb, Felicity Ng, Seetal Dodd, Ashley I Bush, Gin S Malhi
JOURNAL OF CLINICAL PSYCHIATRY | PHYSICIANS POSTGRADUATE PRESS | Published : 2014
OBJECTIVE: Major depressive disorder (MDD) is one of the most common psychiatric disorders, conferring considerable individual, family, and community burden. To date, treatments for MDD have been derived from the monoamine hypothesis, and there is a paucity of emerging antidepressants, especially with novel mechanisms of action and treatment targets. N-acetylcysteine (NAC) is a redox-active glutathione precursor that decreases inflammatory cytokines, modulates glutamate, promotes neurogenesis, and decreases apoptosis, all of which contribute to the neurobiology of depression. METHOD: Participants with a current episode of MDD diagnosed according to DSM-IV-TR criteria (N = 252) were treated w..View full abstract
Awarded by National Health and Medical Research Council
Awarded by NHMRC
The authors would like to acknowledge financial support from the National Health and Medical Research Council (APP628395) and Australian Rotary Health. Dr Berk is supported by a NHMRC Senior Principal Research Fellowship (1059660). The authors would also like to acknowledge service support provided by Barwon Health, the Bendigo Health Care Group, the Cooperative Research Centre for Mental Health, and the Royal North Shore Hospital.